TD Cowen on Avalo Therapeutics (AVTX): 'Risk/Reward Skewed To Significant Upside For AVTX-009 Phase II' Feb 24, 2026 09:14AM
Guggenheim Starts Avalo Therapeutics Inc. (AVTX) at Buy Feb 2, 2026 06:09AM
H.C. Wainwright Reiterates Buy Rating on Avalo Therapeutics Inc. (AVTX) Jan 15, 2026 06:45AM
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note Dec 22, 2025 07:06AM
Mizuho Starts Avalo Therapeutics Inc. (AVTX) at Outperform Dec 17, 2025 04:03PM


Oct 1, 2025 07:00AM Avalo Therapeutics names Taylor Boyd chief business officer
Sep 18, 2025 06:58AM Avalo Therapeutics Inc. (AVTX) PT Raised to $25 at H.C. Wainwright
Sep 18, 2025 06:13AM Oppenheimer Reiterates Outperform Rating on Avalo Therapeutics Inc. (AVTX)
Sep 5, 2025 05:29AM TD Cowen Starts Avalo Therapeutics Inc. (AVTX) at Buy
Aug 15, 2025 06:10AM Cantor Fitzgerald Starts Avalo Therapeutics Inc. (AVTX) at Overweight
Aug 7, 2025 09:33AM Avalo Therapuetics (AVTX) Misses Q2 EPS by 192c
Jul 22, 2025 08:34AM Stifel Reiterates Buy Rating on Avalo Therapeutics Inc. (AVTX)
Jun 30, 2025 01:43PM BTIG Reiterates Buy Rating on Avalo Therapeutics Inc. (AVTX)
Jun 18, 2025 07:01AM Avalo Therapuetics (AVTX) Appoints Rita Jain to its Board
Jun 2, 2025 06:37AM H.C. Wainwright Assumes Avalo Therapeutics Inc. (AVTX) at Buy
May 13, 2025 06:27AM Avalo Therapuetics (AVTX) Misses Q1 EPS by 125c
Mar 26, 2025 07:02AM Avalo Therapuetics (AVTX) Appoints Michael Heffernan as Chairman of the Board
Mar 25, 2025 12:24AM Jefferies Starts Avalo Therapeutics Inc. (AVTX) at Buy
Mar 24, 2025 04:07PM Stifel Starts Avalo Therapeutics Inc. (AVTX) at Buy
Mar 24, 2025 06:32AM Oppenheimer Reiterates Outperform Rating on Avalo Therapeutics Inc. (AVTX)
Feb 28, 2025 06:28AM Piper Sandler Starts Avalo Therapeutics Inc. (AVTX) at Overweight
Jan 2, 2025 07:02AM Avalo Therapuetics (AVTX) Appoints Jennifer Riley as Chief Strategy Officer
Dec 19, 2024 06:05AM BTIG Starts Avalo Therapeutics Inc. (AVTX) at Buy
Nov 12, 2024 07:06AM Avalo Therapuetics (AVTX) Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Oct 8, 2024 12:29PM Oppenheimer Reiterates Outperform Rating on Avalo Therapeutics Inc. (AVTX)
Oct 8, 2024 07:01AM Avalo Therapuetics (AVTX) First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Aug 15, 2024 06:38AM Oppenheimer Reiterates Outperform Rating on Avalo Therapeutics Inc. (AVTX)
Aug 12, 2024 07:59AM Avalo Therapuetics (AVTX) Misses Q2 EPS by 1407c
Jul 16, 2024 07:01AM Avalo Therapuetics (AVTX) Appoints Mittie Doyle as Chief Medical Officer
Jul 9, 2024 07:02AM Avalo Therapuetics (AVTX) Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Jun 24, 2024 04:02PM Avalo Therapuetics (AVTX) Appoints Paul Varki as Chief Legal Officer